OptimizeRx Corp

Listed Company

OPRXCIK 0001448431NasdaqNon-AcceleratedSmaller ReportingServices-Business Services, NecNevadaFY ends Dec 31

Period

FY 2025

Revenue

$109.43M

Net Income

$5.13M

Total Assets

$176.92M

Equity

$128.29M

Shares Out

18.77M

Op. Cash Flow

$18.71M

OPRX$6.72−52.10% · past yearDBEQ Basic

Daily closing prices

Business

OptimizeRx is a digital healthcare technology company that provides AI-enabled marketing solutions for life sciences brands to engage healthcare providers and patients. The company offers proprietary solutions including the Dynamic Audience Activation Platform (DAAP) for precision targeting, Micro-Neighborhood Targeting (MNT) for privacy-first consumer marketing, audience profiling, media execution, pharmacy alerts, and financial messaging across omnichannel networks. OptimizeRx operates a point-of-care network reaching over two million U.S. healthcare providers and serves pharmaceutical manufacturers through direct sales and agency partnerships.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	109	92	72	62	61
Cost of revenues, exclusive of depreciation and amortization presented separately below	36	33	29	23	26
Gross profit	74	59	43	39	36
Stock-based compensation	7	11	—	—	5
Impairment charges	368,000	7	—	—	—
Depreciation and amortization	4	4	2	2	2
Other general and administrative expenses	50	50	44	—	28
Total operating expenses	62	73	69	51	35
Income (loss) from operations	12	−14	−26	−12	361,100
Interest expense	−5	−6	−1	—	—
Other income	198,000	152,000	500,000	—	—
Interest income	353,000	329,000	2	852,298	16,979
Total other expenses, net	−5	−6	1	852,298	—
Income (loss) before provision for income taxes	7	−19	−25	−11	378,079
Income tax expense	−2	−725,000	8	—	—
Net income (loss)	5	−20	−18	−11	378,079
Weighted average number of shares outstanding basic (in shares)	19	18	17	18	17
Weighted average number of shares outstanding diluted (in shares)	19	18	17	18	18
Income (loss) per share basic (in dollars per share)	0.28	−1.1	−1.03	−0.64	0.02
Income (loss) per share diluted (in dollars per share)	0.27	−1.1	−1.03	−0.64	0.02

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	23	13	14	18	85
Accounts receivable, net of allowance for credit losses of $260 and $335 at December 31, 2025 and 2024, respectively	38	38	36	22	25
Taxes receivable	752,000	0	1	—	—
Prepaid expenses and other	3	2	—	2	6
Total current assets	65	54	54	99	115
Property and equipment, net	106,000	150,000	149,000	137,448	143,818
Goodwill	71	71	78	23	15
Patent rights, net	5	6	6	—	2
Technology assets, net	7	8	9	8	5
Tradename and customer relationships, net	29	32	34	—	—
Operating lease right-of-use assets	404,000	366,000	573,000	235,320	328,820
Security deposits and other assets	28,000	296,000	—	5,051	12,859
Total other assets	112	117	129	36	26
TOTAL ASSETS	177	171	183	135	141
Current portion of long-term debt	4	2	2	—	—
Accounts payable	2	2	2	2	606,808
Accrued expenses	12	8	8	3	3
Revenue share payable	3	5	6	4	4
Taxes payable	0	318,000	49,000	—	—
Current portion of lease liabilities	193,000	168,000	222,000	89,902	90,982
Deferred revenue	503,000	473,000	172,000	164,000	—
Total current liabilities	21	19	18	8	9
Long-term debt, net	21	31	34	—	—
Lease liabilities, net of current portion	234,000	209,000	371,000	144,532	236,726
Deferred tax liabilities, net	6	4	4	—	—
Total liabilities	49	54	57	9	10
Commitments and contingencies (See Note 16)	—	—	—	—	—
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2025 and 2024, respectively	0	0	—	—	—
Common stock, $0.001 par value, 166,666,667 shares authorized, 20,500,986 and 20,194,697 shares issued at December 31, 2025 and 2024, respectively	20,000	20,000	20,000	18,289	17,861
Treasury stock, $0.001 par value,$1,741,397 shares purchased at December 31, 2025 and 2024	−2,000	−2,000	—	—	—
Additional paid-in-capital	208	201	191	173	167
Accumulated deficit	−79	−84	−64	−47	−35
Total stockholders equity	128	117	127	126	131
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	177	171	183	135	141

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Bad debt expense	0	208,000	666,000	363,512	80,000
Stock-based compensation	7	11	—	—	—
Amortization of debt issuance costs	1	835,000	211,000	—	—
Accounts receivable	460,000	−2	−9	2	−7
Prepaid expenses and other assets	−467,000	811,000	−573,000	3	−1
Accounts payable	−520,000	−72,000	−1	943,171	−11,442
Revenue share payable	−2	−453,000	2	−387,776	−591,652
Accrued expenses and other liabilities	3	1	1	—	—
Operating lease liabilities	12,000	0	—	226	−3,891
Taxes receivable and payable	−1	0	—	—	—
Deferred tax liabilities	1	1	—	—	—
Deferred loan fees	−250,000	−250,000	—	—	—
Deferred revenue	30,000	301,000	−67,000	—	—
NET CASH PROVIDED BY OPERATING ACTIVITIES	19	5	−7	11	726,039
Purchases of property and equipment	−58,000	−112,000	−87,000	−81,005	−100,322
Capitalized software development costs	126,000	−338,000	—	—	—
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	68,000	−450,000	−25	−58	−485,999
Repayment of long-term debt	−8	−4	−2	—	—
Cash paid for employee withholding taxes related to the vesting of restricted stock units	−1	−911,000	—	—	—
Proceeds from exercise of stock options, net of cash paid for withholding taxes	352,000	0	—	1	5
NET CASH USED IN FINANCING ACTIVITIES	−9	−5	28	−19	74
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	10	−472,000	−4	−66	74
Cash paid for interest	4	6	1	—	—
Cash paid for income taxes	2	161,000	48,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is OptimizeRx Corp's CIK number?

OptimizeRx Corp's SEC CIK number is 0001448431 (1448431). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find OptimizeRx Corp's SEC filings?

All of OptimizeRx Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did OptimizeRx Corp last report earnings?

OptimizeRx Corp (OPRX) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001448431-26-000009). This is OptimizeRx Corp's most recent earnings filing of record — not a forecast of its next earnings date.

What is OptimizeRx Corp's most recent earnings 8-K?

OptimizeRx Corp's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001448431-26-000009. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View OptimizeRx Corp's latest earnings 8-K →
Look up any company's CIK number →